BDX Waters Deal Closes: $4B Cash, Buybacks & Spin.

BDX closes Waters reverse Morris Trust — immediate capital and corporate reset

On February 9, 2026, Becton, Dickinson and Company (BDX) completed the previously announced combination of its Biosciences & Diagnostic Solutions unit with Waters Corporation via a Reverse Morris Trust structure. The deal, supported by near-unanimous shareholder approval and necessary regulatory clearances, delivers roughly $4 billion in cash proceeds to BD and marks a key step in its transformation into a more focused medical-technology company.

Deal mechanics and near-term financial effects

Reverse Morris Trust and approvals

The Reverse Morris Trust approach allowed BD to separate the Biosciences & Diagnostic Solutions business while merging it with Waters in a tax-efficient manner. Shareholder votes and regulatory milestones were cleared in recent weeks, including a favorable IRS determination that smoothed the path to closing. The timing of the close crystallizes the company’s post-transaction capital position and legal structure.

Capital allocation: buybacks, debt reduction and dividends

Management has stated at the annual shareholder meeting that at least 50% of the roughly $4 billion in cash proceeds will be directed to share repurchases, with the remainder targeted toward debt reduction. BD also reaffirmed its commitment to maintaining a reliable dividend, announcing a $1.05 per share dividend payable March 31, 2026 (ex-dividend date March 10). The combination of buybacks and reduced leverage should improve per-share metrics, free-cash-flow coverage, and flexibility for targeted tuck-in acquisitions.

Product and technology momentum supporting the new BD

AI-enabled Research Cloud 7.0

BD launched Research Cloud 7.0 earlier this year, integrating an AI-driven module called BD Horizon Panel Maker. The tool accelerates design of immunology and oncology flow-cytometry panels and streamlines workflows for labs using BD FACSDiscover instruments. This offering reinforces BD’s position in preclinical and translational research by improving lab throughput and reproducibility.

FDA clearance and device pipeline

In mid-January 2026 BD received FDA 510(k) clearance for its EnCor EnCompass™ Breast Biopsy and Tissue Removal System. The device delivers 360° sampling and variable vacuum settings with multiple probe options—features intended to enhance diagnostic yield in breast procedures. The company plans a commercial rollout in early 2026, which should add incremental revenue in breast health and image-guided interventional tools.

Strategic partnerships and sustainability pilots

BD expanded its biologics-delivery capabilities through a partnership with Ypsomed to develop a 5.5 mL Neopak™ XtraFlow™ glass prefillable syringe for high-viscosity subcutaneous biologics, compatible with Ypsomed’s YpsoMate® 5.5 autoinjector. Feasibility samples are expected mid‑2026. Separately, BD and Envetec ran a closed-loop recycling pilot converting polystyrene Petri dishes into clean polymer feedstock, reflecting a push toward circular manufacturing and potential long-term cost and sustainability benefits.

Stock dynamics and investor implications

BDX shares have shown resilience around the transaction announcement. As of early February, the stock traded well under its 52-week high but rallied alongside broader equity gains. The Waters deal’s cash proceeds and the firm’s explicit buyback plan are the clearest drivers for improved per-share metrics in the near term. Reduced debt and a concentrated product portfolio should also simplify analyst modeling and valuation approaches.

What to monitor next

• Execution of the announced share repurchase program and its pace relative to cash inflows.
• Timing and scale of debt paydown and any changes to credit metrics or interest expense.
• Commercial uptake and reimbursement dynamics for EnCor EnCompass in breast procedures.
• Adoption metrics and customer feedback for Research Cloud 7.0 and the BD Horizon Panel Maker.
• Progress on the Ypsomed syringe feasibility and potential new supply agreements with pharma partners.

Conclusion

The closing of the Waters transaction represents a pivotal liquidity and strategic reset for Becton, Dickinson. With a clear capital-allocation directive—heavy on buybacks and debt reduction—paired with fresh product clearances and AI-driven research tools, BD enters a new phase focused on operational simplicity and shareholder returns. Investors and sector observers should watch execution closely: timely repurchases, effective debt reduction, and successful commercialization of the company’s recent innovations will determine whether this structural move translates into sustained earnings-per-share accretion and valuation re-rating.